publication date: Apr. 12, 2019

Your PBM primer: Senate Finance Committee hearing focuses on the mysteries of pharmacy benefit managers—their power and role in rising drug prices

By Claire Dietz and Paul Goldberg

Pharmacy benefit managers, like climate change, germs and, possibly, God, are all around, and if we could clear a few hours, it would be good to learn enough about them to sustain a cocktail party conversation.

Earlier this week, the Senate Committee on Finance trained a Klieg light on PMBs and the role they play in escalating America’s drug prices.

“PBMs negotiate with the drug companies, as well as pharmacies, to arrive at a price for a drug and its ultimate cost,” Sen. Chuck Grassley (R-IA), committee chairman, said at the hearing April 9. “In addition to negotiating prices, PBMs also determine what drugs are covered and what patients pay out-of-pocket.

“The current system is so opaque that it’s easy to see why there are many questions about PBMs’ motives and practices. Mergers and vertical integration is another area that has increasingly prompted concern.

“All of the PBMs here today are owned by or affiliated with an insurance plan. In many cases, the combined company also owns pharmacies and other players in the health industry,” Grassley said. “It’s important we look to see whether … Continue reading Your PBM primer: Senate Finance Committee hearing focuses on the mysteries of pharmacy benefit managers—their power and role in rising drug prices

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.